Eligibility criteria used to define severe SCD by the Collaborative Group Study of Marrow Transplantation for Sickle Cell Anemia
| One or more of the following3 : . |
|---|
| Stroke or central nervous system event lasting longer than 24 hours |
| Acute chest syndrome with recurrent hospitalizations or previous exchange transfusions |
| Recurrent vaso-occlusive pain (≥2 episodes per year for several years) or recurrent priapism |
| Impaired neuropsychological function and abnormal cerebral MRI scan |
| Stage I or II sickle lung disease |
| Sickle nephropathy (moderate or severe proteinuria or a glomerular filtration rate 30% to 50% of the predicted normal value) |
| Bilateral proliferative retinopathy and major visual impairment in at least one eye |
| Osteonecrosis of multiple joints |
| Red cell alloimmunization (≥2 antibodies) during long-term transfusion therapy |
| One or more of the following3 : . |
|---|
| Stroke or central nervous system event lasting longer than 24 hours |
| Acute chest syndrome with recurrent hospitalizations or previous exchange transfusions |
| Recurrent vaso-occlusive pain (≥2 episodes per year for several years) or recurrent priapism |
| Impaired neuropsychological function and abnormal cerebral MRI scan |
| Stage I or II sickle lung disease |
| Sickle nephropathy (moderate or severe proteinuria or a glomerular filtration rate 30% to 50% of the predicted normal value) |
| Bilateral proliferative retinopathy and major visual impairment in at least one eye |
| Osteonecrosis of multiple joints |
| Red cell alloimmunization (≥2 antibodies) during long-term transfusion therapy |